CD19 Full-Length Proteins, Antibodies & Cell Lines

CD19 is one of the most widely studied B-cell lineage surface proteins. Its expression begins at relatively early stages of B-cell development and is maintained through most mature B-cell populations before declining during plasma-cell differentiation. Functionally, CD19 acts as an important regulator of B-cell receptor signaling and helps control activation thresholds, proliferation, differentiation, and immune responses. Because of its broad and relatively lineage-restricted cell-surface expression, CD19 has become a central target in B-cell malignancy research and has been extensively explored for monoclonal antibodies, ADCs, bispecific and multispecific molecules, and engineered cell therapies. For CD19-targeting biologics, it is often important to assess not only binding to recombinant ECD proteins but also recognition of the native membrane conformation, epitope location, species cross-reactivity, and cellular binding properties.

DIMA BIOTECH offers a comprehensive CD19 portfolio including recombinant ECD proteins with different regions and engineered designs, human and cynomolgus proteins, biotinylated proteins, PeptiNanodisc and Synthetic Nanodisc full-length CD19 membrane proteins, flow cytometry and WB antibodies, biosimilar reference antibodies, PE/biotin conjugates, and a CD19-overexpressing K562 stable cell line. ECD and full-length Nanodisc proteins provide complementary tools for antibody screening, epitope analysis, and native-like membrane-protein binding studies. Stable cells support FACS and cell-binding assays, while tissue slides enable IHC evaluation. DIMA BIOTECH also maintains lead CD19 antibody molecules that can be further advanced through humanization, affinity maturation, antibody engineering, and functional validation.